🇺🇸 FDA
Pipeline program

Placebo to BI 765423, BI 765423

1493-0002

Phase 2 small_molecule active

Quick answer

Placebo to BI 765423, BI 765423 for Idiopathic Pulmonary Fibrosis (IPF) is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Idiopathic Pulmonary Fibrosis (IPF)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials